Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
Add more filters










Publication year range
1.
J Chemother ; 23(6): 354-7, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22233820

ABSTRACT

Many drugs can be used for adjuvant therapy of breast cancer, including anthracyclines, cyclophosphamide, 5-fluorouracil (5-fU) and, recently, taxanes (TXT) have shown promising results. 5-FU blocks thymidylate synthase (TS) which cross-links p53 mRNA, inhibiting its synthesis. TS overexpression is one of the main mechanisms involved in 5-FU drug resistance. Enough p53 mutations can confer resistance to chemotherapy using anthracyclines and 5-FU, while are associated with improved responses to TXT. The aim of this study was to examine the TS and p53 levels in tumor samples and to compare the efficacy of FEC (5-FU, epirubicin, cyclophosphamide) and TXT chemotherapy in a group of patients with differing TS and p53 status. We examined 84 breast tumor samples using immunohistochemistry. TS and p53 levels were inversely related, and TS and p53 positivity was significantly associated with the failure of FEC treatment and with a good response to TXT therapy (p <0.001). This confirms the predictive role of these two markers, which should be considered when choosing the appropriate adjuvant therapy for breast cancer.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Bridged-Ring Compounds/therapeutic use , Taxoids/therapeutic use , Thymidylate Synthase/metabolism , Tumor Suppressor Protein p53/metabolism , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Breast Neoplasms/enzymology , Breast Neoplasms/genetics , Chemotherapy, Adjuvant , Cyclophosphamide/administration & dosage , Epirubicin/administration & dosage , Female , Fluorouracil/administration & dosage , Humans , Immunohistochemistry , Neoplasm Staging , Prognosis , Thymidylate Synthase/antagonists & inhibitors , Thymidylate Synthase/genetics , Tumor Suppressor Protein p53/genetics
2.
J Nucleic Acids ; 20102010 Jan 26.
Article in English | MEDLINE | ID: mdl-20725619

ABSTRACT

Thymidylate synthase (TS) catalyzes methylation of dUMP to dTMP and it is the target for the 5-Fluorouracil (5-FU) activity. Barbour et al. showed that variant structural forms of TS in tumour cell lines confer resistance to fluoropyrimidines. We planned to perform the whole TS gene structure by means of sequencing techniques in human colorectal cancer (CRC) samples to try to identify the presence of any possible TS variant form that could be responsible of fluoropyrimidines drug resistance and of the worse prognosis. We performed the TS-DNA gene sequence in 68 CRC from patients of A, B, and C Dukes' stages and different histological grade, but we did not find any mutation in the TS-DNA structure. In the future we intend to widen the TS structure analysis to the metastatic CRCs, because due to their higher genomic instability, they could present a TS variant form responsible of the fluoropyrimidines drug resistance and the worse prognosis.

3.
Nucleosides Nucleotides Nucleic Acids ; 25(9-11): 1193-6, 2006.
Article in English | MEDLINE | ID: mdl-17065089

ABSTRACT

Breast cancer is a heterogeneous disease, so therapeutic predictive biological markers need to be identified. To date an accurate evaluation of predictive markers is mainly done at the primary site; however, the main goal of adjuvant therapy for breast cancer is the control of micrometastases. The aim of this study is to assess as therapeutic and/or prognostic marker, the proliferation status of primary tumors and involved nodes as measured by Ki67 and thymidylate synthase (TS) expression, in 30 breast cancer node positive patients. TS is the main target of 5-fluorouracil (5-FU) activity, and its overexpression is one of the mechanisms of 5-FU drug resistance; however, in some studies its absence is responsible for a worse response to 5-FU. Our results show that malignant cells of involved nodes were in a post mitotic phase of the cell cycle, and show a low proliferation index and TS expression, while the primary tumours and controls, were strongly positive. On these basis we can hypothesize that these cells could be less sensitive to 5-FU. Further studies are necessary to identify other mechanisms responsible for their metastasing capability and/or for their aggressiveness.


Subject(s)
Breast Neoplasms/metabolism , Gene Expression Regulation, Enzymologic , Gene Expression Regulation, Neoplastic , Ki-67 Antigen/biosynthesis , Thymidylate Synthase/biosynthesis , Antigens, Neoplasm/biosynthesis , Antimetabolites, Antineoplastic/pharmacology , Breast Neoplasms/pathology , Cell Proliferation , Female , Fluorouracil/pharmacology , Humans , Lymphatic Metastasis , Neoplasm Metastasis , Prognosis
4.
Anticancer Res ; 26(6B): 4357-60, 2006.
Article in English | MEDLINE | ID: mdl-17201155

ABSTRACT

UNLABELLED: The aim of the study was to verify by Ki-67 immunostaining if any difference exists in the cell proliferating fraction between primary breast tumors (PTs) and matching positive axillary lymph nodes (ALNs). PATIENTS AND METHODS: Immunohistochemistry with the monoclonal antibody against Ki-67 was performed in 160 node-positive breast carcinomas and in their respective lymph node metastases. RESULTS: An increase of Ki-67 immunoreactive cells in ALN compared with that of PTs was observed in 84% of cases (ALN: mean 17%, PTs: mean 8%; p < 0.001), whereas 16% of the cases showed Ki-67 value two to six times lower in the ALNs than in the corresponding PTs (ALN: mean 3.2%, PTs mean 12.5%; p < 0.005). The decrease of Ki-67 positive cells in the ALN was independent from the histotype and the histological grade of the tumor. CONCLUSION: A different cell proliferation fraction between PTs and matching positive ALNs was demonstrated and underlined that the existence of a group of patients with decreased number of Ki-67 immunoreactive cells in lymph node metastases compared with that of the primary tumors could be taken into account in the choice of therapeutic strategy.


Subject(s)
Breast Neoplasms/immunology , Ki-67 Antigen/immunology , Lymphatic Metastasis/immunology , Female , Humans
5.
Nucleosides Nucleotides Nucleic Acids ; 23(8-9): 1377-9, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15571262

ABSTRACT

5-Fluorouracil (5FU) is the main drug used for the treatment of colorectal cancer (CRC) and Thymidilate Synthase (TS) is its target enzyme. TS gene has regulatory tandemly repeated sequences in its 5' and 3'untraslated region (5'-3' UTR). CRC often shows a kind of genomic instability called Microsatellite Instability (MSI) that is associated with TS levels and survival. Our data show that the genotype 2R/2R (homozygosity for 2 tandem repeat sequences in the 5'UTR) is more frequently associated with MSI+ and lower TS levels. More over we did not find any significant association between the 2R/3R (heterozygosity for 2 and 3 tandem repeat sequences in the 5'UTR) and 3R/3R (homozygosity for 3 tandem repeat sequences in the 5' UTR) genotypes with the MSI+ and MSI-, while these genotypes were associated with a higher TS expression. As a consequence we can hypothesise that patients bearing CRC with the MSI+, the 2R/2R genotype and with low TS levels could have a better prognosis and they could not be drug resistant.


Subject(s)
Colorectal Neoplasms/genetics , Drug Resistance, Neoplasm , Microsatellite Repeats , Polymorphism, Genetic , Thymidylate Synthase/genetics , Cell Line, Tumor , Genotype , Heterozygote , Humans , Phenotype , Protein Biosynthesis , RNA, Messenger/metabolism , Transcription, Genetic
6.
Eur J Cancer ; 40(18): 2845-50, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15571969

ABSTRACT

Thymidylate Synthase (TS) is the key enzyme for DNA synthesis pathways and is inhibited by 5-fluorouracil (5FU). The aim of this work was to study TS expression and the proliferation rate in the different histological types of colorectal carcinoma (CRC). 50 patients with CRC were included in this study and evaluated immunohistochemically using the monoclonal antibodies, TS106 and Ki67. 20 tumours were of the intestinal type, 15 cases were signet ring cell carcinoma (SRCCs) and 15 cases were "mixed-type", with at least two different histological components. Intestinal and mucinous histotypes were positive for TS and Ki67, while "signet ring cell" samples were negative or showed only weak and focal positivity for both the TS and Ki67 antibodies. Our results show that signet ring cells (that are also often present in intestinal and mucinous carcinomas), are in the post-mitotic phase of the cell cycle and show a low proliferation index and TS expression. As TS is the key enzyme for DNA synthesis pathways and is inhibited by 5-fluorouracil (5FU), we can hypothesise that TS expression levels in the different histotypes of CRC could affect the potential responsiveness of these tumours to fluoropyrimidine chemotherapy, with a low efficacy being expected in signet ring cell areas.


Subject(s)
Carcinoma, Signet Ring Cell/enzymology , Colorectal Neoplasms/enzymology , Neoplasm Proteins/metabolism , Thymidylate Synthase/metabolism , Adult , Aged , Female , Humans , Immunohistochemistry , Ki-67 Antigen/metabolism , Male , Middle Aged
7.
Anticancer Res ; 24(6): 3875-80, 2004.
Article in English | MEDLINE | ID: mdl-15736425

ABSTRACT

BACKGROUND: Microsatellite instability (MSI) is a biological characteristic of most tumours, being involved in 85% of hereditary non-polyposis colorectal cancer (HNPCC). It also occurs in 10-15% of sporadic colorectal cancers (CRC). HNPCC appears to be caused by germline mutations in mismatch repair (MMR) genes, which are responsible for repairing single base-pair mismatches. MSI is also associated with a better response of CRC to adjuvant chemotherapy with fluoropyrimidines. We investigated any relationship between the MSI status and the TSmRNA expression, the polymorphisms of 5-Fluorouracil (5-FU cellular target, the enzyme thymidylate synthase (TS) and TS expression evaluated by means of immunohistochemistry. MATERIALS AND METHODS: A series of 80 colorectal cancers was evaluated for MSI and polymorphisms in the 3'UTR and the 5'UTR of the TS gene by a PCR assay. TSmRNA was quantified by real-time PCR and the TS expression by immunohistochemical assay. RESULTS: There was no significant association between the polymorphisms in the TS gene and the MSI or between the TSmRNA expression and the MSI status. CRC with a 3R/3R or 2R/3R genotype showed a significantly higher TSmRNA expression than those with the 2R/2R genotype (p = 0.001 and p = 0.028, respectively). Another significant association was found between the TSmRNA expression and the TS immunohistochemical determination (p = < 0.05). No association was found between the polymorphism of the 3'UTR and the TSmRNA expression. CONCLUSION: Our data show that there is no association between MSI status and the polymorphisms in the 3' and 5' UTRs and the TS expression. Tumour samples displaying the 3R/3R or 2R/3R genotype of TS have higher TSmRNA levels than the 2R/2R genotype. Polymorphic variant of the 3'UTR does not influence the TSmRNA level. We found a relationship between the TSmRNA expression, evaluated by real-time PCR, and with the TS level determined by immunohistochemical assay. Thus, genotyping of the 5'UTR and quantification of the TSmRNA expression in human CRC could be considered as predictors for response to SFU-based chemotherapy. The evaluation of the TS expression by means of immunohistochemistry assay remains a safe and reliable assay in CRC.


Subject(s)
Colorectal Neoplasms/enzymology , Colorectal Neoplasms/genetics , Genomic Instability/genetics , RNA, Messenger/biosynthesis , Thymidylate Synthase/genetics , 5' Untranslated Regions , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal/chemistry , Female , Humans , Immunohistochemistry , Male , Microsatellite Repeats/genetics , Middle Aged , Polymorphism, Genetic , Promoter Regions, Genetic , RNA, Messenger/genetics , Thymidylate Synthase/biosynthesis
8.
J Chemother ; 13(5): 519-26, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11760216

ABSTRACT

5-Fluorouracil (5-FU) is a pyrimidine antimetabolite active against colorectal carcinoma and other malignancies of the digestive tract. Over-expression or mutation of thymidylate synthase (TS), the target enzyme of the 5-FU metabolite, 5-fluorodeoxyuridine monophosphate, is strictly correlated with cancer cell resistance to 5-FU. On this basis we investigated whether TS is a potential target for active specific immunotherapy of human colon carcinoma, which acquires resistance to 5-FU. Three TS-derived epitope peptides which fit defined amino acid consensus motifs for HLA-A2.1 binding were synthesized and investigated for their ability to induce human TS-specific cytotoxic T cell (CTL) responses in vitro. CTL lines specific for each peptide were established by stimulating peripheral blood mononuclear cells (PBMC) from an HLA-A2.1+ healthy donor with autologous dendritic cells loaded with TS peptide. Specific CTL lines showed HLA-A2.1-restricted cytotoxicity in vitro to HLA-A2.1+ target cells pulsed with the specific TS peptide and to HLA-class I matching colon carcinoma target cells over-expressing TS enzyme after exposure to 5-FU. Recognition by CTL lines suggests that these TS peptides may be potential candidates for use in a peptide-based vaccine against 5-FU resistant colon carcinoma.


Subject(s)
Antimetabolites, Antineoplastic/pharmacology , Carcinoma/immunology , Colonic Neoplasms/immunology , Fluorouracil/pharmacology , HLA-A2 Antigen/immunology , T-Lymphocytes, Cytotoxic/immunology , Thymidylate Synthase/biosynthesis , Cancer Vaccines , Carcinoma/pathology , Cell Line , Colonic Neoplasms/pathology , Drug Resistance, Neoplasm , Epitopes, T-Lymphocyte , Flow Cytometry , Humans , Peptides , Thymidylate Synthase/pharmacology , Tumor Cells, Cultured
9.
Anticancer Res ; 20(6B): 4347-50, 2000.
Article in English | MEDLINE | ID: mdl-11205269

ABSTRACT

Structural changes in the macromolecular targets of pharmacological agents can result in alterations in the efficacy of these agents. In previous studies Berger et al. (1) identified a variant structural form of thymidylate synthase (TS) that is associated with relative resistance to 5-fluoro-2'-deoxyuridine, in a human colonic tumor cell line. They observed that expression of the variant TS, which differs from the normal form by a tyrosine to histidine substitution at residue 33, confers a 4-fold level of drug resistance in mammalian cells, as well as in bacteria. Now we report on the use of RT-PCR techniques to see if that variant TS form could be present in human samples from patients who underwent surgery for primary colorectal cancer and been previously untreated and to try to find relationships between that hypothetical variant TS form and the 5-Fluorouracil treatment. The possible role of Tyr-33 in 5-fluoropyrimidine-mediated inhibition of TS is discussed.


Subject(s)
Colonic Neoplasms/genetics , Neoplasm Proteins/genetics , Point Mutation , Rectal Neoplasms/genetics , Thymidylate Synthase/genetics , Adenocarcinoma/enzymology , Adenocarcinoma/genetics , Adenocarcinoma/pathology , Aged , Colonic Neoplasms/enzymology , Colonic Neoplasms/pathology , Female , Histidine , Humans , Male , Neoplasm Staging , Rectal Neoplasms/enzymology , Rectal Neoplasms/pathology , Reverse Transcriptase Polymerase Chain Reaction , Tyrosine
10.
Anticancer Res ; 18(3A): 1515-20, 1998.
Article in English | MEDLINE | ID: mdl-9673363

ABSTRACT

Inhibition of Thymidylate Synthase (TS) by the 5-Fluorouracil (5Fu) active metabolite Fluoro-deoxy-uridine-monophosphate (FdUMP) is considered to be the main mechanism of action of 5Fu. TS level from tumors and normal mucosa of 62 untreated patients who underwent surgery for primary colorectal adenocarcinoma was performed. The aim of this study was to evaluate the possibility of considering the TS level as a prognostic factor of the disease. A large variation in the level of the enzyme was found among tumors. Our data demonstrate that there is no association with age, sex, and tumor size; however there are significant relationships between TS levels and staging and histological grading. In fact the TS values are higher in Dukes' A and in G1 than in Dukes' D and G3 tumors (p < 0.05). Another significant association has been found between the TS level and tumor site: pts with right colon neoplasias had higher TS levels than pts with left and rectum ones. An interesting trend was found between the TS levels and survival parameters. Pts who had lower TS levels had a significantly increased risk of death (p < 0.05) over pts with a higher outcome. Our data support the hypothesis that a high TS level is a favourable prognostic factor in human untreated colorectal carcinomas according to our previous preliminary data (1).


Subject(s)
Adenocarcinoma/surgery , Colorectal Neoplasms/surgery , Thymidylate Synthase/metabolism , Adenocarcinoma/enzymology , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Aged , Biomarkers, Tumor/analysis , Colorectal Neoplasms/enzymology , Colorectal Neoplasms/mortality , Colorectal Neoplasms/pathology , Female , Humans , Intestinal Mucosa/enzymology , Intestinal Mucosa/pathology , Male , Middle Aged , Neoplasm Staging , Prognosis , Survival Rate , Thymidylate Synthase/analysis , Time Factors
11.
Anticancer Res ; 15(3): 901-6, 1995.
Article in English | MEDLINE | ID: mdl-7645979

ABSTRACT

5-Fluorouracil is the drug chosen for the treatment of patients with advanced colorectal carcinoma; its major site of action is thymidylate synthase (TS), resulting in pronounced and prolonged inhibition of DNA synthesis. The aim of this study was to evaluate the possibility of considering TS level in human colorectal carcinomas of previously untreated patients (pts) as a prognostic factor. Our data demonstrate that there is no association with age, sex, tumor site and tumor size; however, there is a relationship between TS levels and staging: in fact, the TS values are higher (P < 0.05) in Dukes-A tumors than in the others. A significant association was also found between the TS levels and survival parameters: in fact, pts with longer disease-free and overall survivals had a significantly increased TS level compared to pts with a poorer outcome (P < 0.05). Moreover, pts with DNA-aneuploid tumors had lower TS level (median = 0.044 pmol/mg protein) than diploid pts who had higher TS level (median = 0.093 pmol/mg protein); however the difference is not significant. Our result are based on preliminary data; however, they seem to support the hypothesis that a high TS level is a favourable prognostic factor in human colorectal carcinoma.


Subject(s)
Adenocarcinoma/pathology , Colorectal Neoplasms/pathology , DNA, Neoplasm/analysis , Ploidies , Thymidylate Synthase/analysis , Adenocarcinoma/metabolism , Adenocarcinoma/mortality , Adenocarcinoma/surgery , Age Factors , Aged , Aneuploidy , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/mortality , Colorectal Neoplasms/surgery , DNA, Neoplasm/genetics , Diploidy , Disease-Free Survival , Female , Humans , Male , Middle Aged , Neoplasm Staging , Predictive Value of Tests , Prognosis , Sex Characteristics , Survival Rate , Thymidylate Synthase/metabolism
12.
Res Commun Chem Pathol Pharmacol ; 82(1): 81-9, 1993 Oct.
Article in English | MEDLINE | ID: mdl-8272575

ABSTRACT

CD1 female mice were treated with doxorubicin (DXR, 5 mg/Kg i.v.) once a week for eight weeks or with lonidamine (LND, 100 mg/Kg i.p.) once a week for eight weeks. Other mice received lonidamine (100 mg/Kg i.p.) immediately before doxorubicin (5 mg/Kg i.v.) administration. The animals were sacrificed four weeks after the last administration and their cardiac morphology was evaluated by means of light microscopy. Lonidamine slightly reduced the extent of the atrial but not of the ventricular alterations caused by DXR. The results seem to indicate that, in this experimental model, lonidamine does not substantially modify the cardiotoxicity induced by doxorubicin.


Subject(s)
Antineoplastic Agents/pharmacology , Doxorubicin/pharmacology , Myocardium/pathology , Animals , Female , Heart/drug effects , Heart Septum/drug effects , Heart Septum/pathology , Heart Ventricles/drug effects , Heart Ventricles/pathology , Indazoles/pharmacology , Mice
13.
Tumori ; 77(3): 219-26, 1991 Jun 30.
Article in English | MEDLINE | ID: mdl-1862549

ABSTRACT

In view of the structural similarity of mitoxantrone to anthracyclines and its ability to intercalate into DNA, we studied its influence on the synthetic processes of DNA and proteins in CD-1 mice tissues. By studying at the DNA level the impairment of 3H-thymidine incorporation and its return to normal, it was found that bone marrow and spleen showed similar behavior, i.e., a rapid return to normal, which occurred before bone marrow cell number and spleen weight returned to basal values. At the cardiac level, the incorporation values of precursors into DNA, reduced by treatment with mitoxantrone, came back very slowly to the control ones. Hepatic DNA showed a lower sensitivity to mitoxantrone. Analysis of 3H-leucine incorporation into three protein fractions of the heart showed that the contractile proteins were the most responsive fractions to mitoxantrone treatment. Experiments on CD-1 mice treated repeatedly with mitoxantrone revealed that the antitumor drug, at the cumulative dose of 8 mg/kg i.v., induced alterations in myocardiac morphology similar qualitatively to those induced by doxorubicin, although smaller quantitatively.


Subject(s)
DNA/biosynthesis , Mitoxantrone/pharmacology , Muscle Proteins/biosynthesis , Myocardium/metabolism , Animals , Bone Marrow/metabolism , Heart/anatomy & histology , Liver/metabolism , Mice , Spleen/metabolism
14.
Res Commun Chem Pathol Pharmacol ; 70(3): 259-72, 1990 Dec.
Article in English | MEDLINE | ID: mdl-2128759

ABSTRACT

CD 1 female mice were treated with Doxorubicin (5 mg/Kg i.v.) once a week for 8 weeks or with Isoproterenol (20 mg/Kg s.c.) once a week for 5 weeks. Other mice were treated with the chelating agent ICRF-187 (100 mg/Kg i.p.) 30 min. before Doxorubicin or Isoproterenol administration. The animals were sacrificed 4 weeks after the last administration and their cardiac morphology was evaluated by means of light microscopy. ICRF-187 significantly lessened the extent and the severity of the cardiac lesions by Doxorubicin (-68%, P less than 0.01 in left atrium; -69%, P less than 0.01 in ventricles) and the extent of those induced by Isoproterenol (-56%, P less than 0.05). These data confirm that ICRF-187 has good activity on Doxorubicin-induced myocardiopathy and provide new information about the "in vivo" effects of the compound on the cardiotoxicity caused by Isoproterenol. Moreover, they seem to confirm that a common event, probably the involvement of metal ions, plays a role in the morphologically different myocardiopathies induced by Doxorubicin or Isoproterenol.


Subject(s)
Doxorubicin/toxicity , Heart/drug effects , Isoproterenol/toxicity , Razoxane/pharmacology , Animals , Doxorubicin/administration & dosage , Doxorubicin/antagonists & inhibitors , Female , Heart Atria/drug effects , Injections, Intravenous , Isoproterenol/antagonists & inhibitors , Mice , Premedication , Quality Assurance, Health Care
16.
Chemioterapia ; 7(1): 53-9, 1988 Feb.
Article in English | MEDLINE | ID: mdl-3163942

ABSTRACT

The cardiac morphology of CD 1 mice undergoing two different schedules of acute (5 day) starvation and that of animals treated with a single dose (15 mg/kg i.p.) of doxorubicin, epirubicin or mitoxantrone were studied by light microscopy. Determinations of heart catalase were also carried out. Mice subjected to moderate starvation had a mean weight reduction of 18.7% and did not show heart morphological damage. A slight increase (38%) of heart catalase specific activity occurred in these animals. In animals subjected to severe starvation the weight loss was 32.2%. In this case considerable heart damage, in the form of myofibrillar loss, and a striking increase of catalase (158.5%) were seen. In the drug groups comparable weight reductions (about 15%) occurred 5 days after the treatment. Moderate heart lesions, represented by myolysis and especially by myocytic microvacuolation, were observed and appeared to be of similar degree in the 3 drug groups. Catalase specific activity increased by 119.9% in the doxorubicin animals, by 73% in the epirubicin mice and by 30.3% in the mitoxantrone ones. Light microscopy made it possible to distinguish between cardiac alterations induced by starvation and those specifically induced by antiblastics. Catalase may be helpful to indicate the existence of heart damage but it does not correlate well with the severity of the lesions by antiblastics. An additional cause of heart catalase elevation might be the free radical generation induced by the anthracyclines but not by mitoxantrone.


Subject(s)
Catalase/analysis , Doxorubicin/toxicity , Mitoxantrone/toxicity , Myocardium/pathology , Starvation/pathology , Animals , Epirubicin , Heart/drug effects , Mice , Myocardium/enzymology , Starvation/enzymology
17.
Tumori ; 73(3): 279-87, 1987 Jun 30.
Article in English | MEDLINE | ID: mdl-3603724

ABSTRACT

In previous studies we reported that teniposide (VM26) induced acute cardiac effects in dogs seem to be related to a release of histamine and that a prior treatment with chlorpheniramine, an H1 histamine blocker, prevents the onset of this phenomenon. Since histamine and other vasoactive substances also seem to be involved in doxorubicin (DXR)-induced acute cardiac effects, experiments were undertaken in the aim to prevent, as in the case of VM26, the onset of this phenomenon by administering chlorpheniramine. Since DXR-induced chronic cardiomyopathy also seems to be related to the same mechanisms involved in the onset of acute cardiac effects induced by this drug, additional studies were carried out to investigate whether a long-term treatment with VM26 could induce in mouse alterations of cardiac morphology similar to those of DXR. In addition, because the mouse is known to be extremely insensitive to histamine, further studies were performed to investigate whether DXR or VM26 administration could induce in this animal model a massive histamine release and whether a long-term treatment with high doses of histamine could elicit, similarly to DXR, alterations in cardiac morphology. The results of our experiments demonstrated that DXR (1.5 mg/kg i.v.) caused in the dog a massive histamine release and a marked impairment of cardiac inotropism. As previously described for VM26, prior treatments with chlorpheniramine completely prevented this phenomenon. Furthermore, DXR administration, at a dose level able to induce cardiac damage in the mouse (2.5 mg/kg i.v.), or that of VM26 (2 mg/kg i.v.) failed to induce a massive histamine release. In addition, long-term treatment with VM26 (2 mg/kg i.v.) or high doses of histamine (100 mg/kg i.v.), unlike DXR, did not elicit in this animal alterations of cardiac morphology. Finally, chlorpheniramine (0.15 or 0.45 mg/kg i.v.) did not prevent the onset of chronic cardiomyopathy induced by DXR in mouse. In conclusion, our results show that the role of histamine in the onset of DXR-induced chronic cardiomyopathy, at least in mouse, remains questionable and suggest that this animal, because of its high natural resistance to histamine, is not a suitable experimental model to investigate the cardiovascular pharmacology of drug-induced histamine release.


Subject(s)
Doxorubicin/adverse effects , Heart/drug effects , Histamine/physiology , Podophyllotoxin/analogs & derivatives , Teniposide/adverse effects , Animals , Chlorpheniramine/pharmacology , Dogs , Female , Histamine/pharmacology , Male , Mice , Myocardium/pathology
19.
Arzneimittelforschung ; 29(6): 901-2, 1979.
Article in English | MEDLINE | ID: mdl-582782

ABSTRACT

Experiments in mice treated with a single 10 mg/kg dose of doxorubicin (adriamycin) i.p. revealed considerable reduction in the incorporation of 3H-thymidine in DNA and of 3H-uridine in RNA, in the spleen and liver, and at mitochondrial and non-mitochondrial level in the heart. Although protein syntheses in the heart and spleen were not reduced by the drug to any great degree, they took 10 days to return to normal; conversely, liver protein syntheses were not inhibited at all and indeed presented signs of stimulation.


Subject(s)
DNA Repair/drug effects , Doxorubicin/pharmacology , Protein Biosynthesis , RNA/biosynthesis , Animals , Kinetics , Liver/metabolism , Mice , Myocardium/metabolism , Spleen/metabolism , Thymidine/metabolism , Uridine/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...